Search

During a phase I trial of interleukin-1 alpha (IL-1 alpha) in patients with ovarian carcinomas, the effects of this treatment on blood granulocyte respiratory burst and locomotive responses were examined. Differences in baseline granulocyte function in patients as well as dose-related effects of IL-1 alpha treatment were observed. Patients enrolled early in the trial (low-dose patients) had significantly lower locomotive responses before treatment than their paired controls; these low responses normalized after 5 days of continuous-infusion IL-1 alpha treatment. Patients enrolled later (high-dose patients) had normal locomotive responses before treatment and IL-1 alpha treatment was associated with suppression of responses to selected stimuli at the end of treatment. Pretreatment respiratory burst responses in both low- and high-dose patient groups were essentially normal, but the rates of granulocyte H2O2 production following phorbol myristate acetate stimulation became significantly less than control values at the end of treatment. In vitro exposure of either patient or control cells to 150 U/ml IL-1 alpha did not alter their locomotive or respiratory burst responses, suggesting the observed in vivo effects were not mediated directly by IL-1 alpha. Treatment with IL-1 alpha is associated with changes in ex vivo granulocyte function that are related to the IL-1 alpha dose. Treatment with low doses of IL-1 alpha may provide a means of normalizing abnormal polymorphonuclear leukocyte function in some patients with ovarian malignancies.

Locomotion and oxidative metabolism of polymorphonuclear leukocytes from 15 patients receiving recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) were examined in vitro. At the end of each GM-CSF treatment course, polymorphonuclear leukocyte (PMN) chemotactic responses were suppressed and no enhancement of formyl-peptide-stimulated superoxide production was observed. The priming of PMN superoxide production normally seen after in vitro GM-CSF exposure was also blunted in these cells. By using control donor PMN, two membrane-fluidizing agents, pentoxifylline and butanol, were shown to normalize suppressed PMN chemotaxis caused by in vitro GM-CSF (1 nM) exposure. Pentoxifylline, but not butanol, also reversed the effects of in vitro GM-CSF on PMN superoxide production. When PMN obtained from six patients at the end of GM-CSF therapy were exposed to pentoxifylline in vitro, the chemotactic suppression typically observed was significantly improved. The data suggest that GM-CSF may affect PMN function via mechanisms involving membrane fluidity or cell deformability or both.

Because it has recently been hypothesized that human milk is antiinflammatory, the effects of aqueous human colostrum on human polymorphonuclear leukocyte (PMN) respiratory burst activity and selected enzymatic activities was examined. Aqueous colostrum was found to spontaneously reduce ferricytochrome C in a concentration-dependent manner, prohibiting use of the standard assay to measure superoxide production. It also caused a significant concentration-dependent prolongation of the lagtime from stimulation of PMN with phorbol myristate acetate to the appearance of hydrogen peroxide. Substitution of an enzymatic peroxide-generating system for PMN did not alter the effect of colostrum. Colostrum also suppressed myeloperoxidase activity and lysozyme activity, but not beta-glucuronidase activity in PMN lysates. Inclusion of colostrum in an in vitro assay of PMN-mediated cell detachment significantly suppressed this PMN-mediated effect. These data demonstrate that aqueous human colostrum significantly interferes with PMN oxygen metabolic and enzymatic activities that are important in the mediation of acute inflammation.

Human colostrum manifests antioxidant properties, being capable of spontaneous reduction of cytochrome c, depletion of polymorphonuclear leukocyte-produced H2O2 and protection of epithelial cells from PMN-mediated detachment. These activities can be electrophoretically concentrated at either 3.5 kD or 50 kD dialysis membranes at mildly alkaline pH. They are progressively lost under increasingly alkaline conditions. They are resistant to 1-mM N-ethylmaleimide. Examination of a series of antioxidant compounds showed that ascorbate manifests several characteristics of colostrum, being able to reduce cytochrome c and deplete H2O2 but not altering PMN-mediated HEp2 cell detachment. Addition of ascorbate oxidase to colostrum decreased its cytochrome c-reducing activity by more than 85%, decreased its H2O2-depleting activity by nearly 50%, but did not alter its ability to protect HEp2 cells, all suggesting heterogeneity of colostral antioxidant activities. Treatment of colostrum with an enzymatic system (xanthine + xanthine oxidase) known to destroy ascorbate's cytochrome c-reducing activity yielded paradoxical results, decreasing colostral cytochrome c reduction in a dose-related manner, while increasing its H2O2-depleting activity. These studies demonstrate that a colostral component similar to ascorbate, a known antioxidant compound is responsible for the majority of colostral cytochrome c-reducing activity, for about half of its H2O2-depleting activity, and little, if any, of its protective effect on HEp2 cells. Thus colostral antioxidant activity is heterogeneous.